bPiDDB (peripherally administered) inhibits nicotine-evoked dopamine (DA) release in nucleus accumbens and decrease intravenous nicotine self-administration in rats[1].
bPiDDB is brain bioavailable following peripheral administration and is transported actively by the blood-brain barrier choline transporter into the central compartment[1].
